Cargando…
Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model
Although numerous chemotherapeutic agents have been evaluated for patients with advanced prostate cancer, none have demonstrated improved survival benefits. Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the regimen, we evaluated the effect of the varied...
Autores principales: | Miyake, H, Hara, S, Arakawa, S, Kamidono, S, Hara, I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363822/ https://www.ncbi.nlm.nih.gov/pubmed/11259104 http://dx.doi.org/10.1054/bjoc.2000.1686 |
Ejemplares similares
-
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
por: Terakawa, T, et al.
Publicado: (2009) -
Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells
por: Cui, Luwei, et al.
Publicado: (2019) -
Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells
por: Li, Wei, et al.
Publicado: (2018) -
Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.
por: Wolf, D. A., et al.
Publicado: (1991) -
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
por: Gustavsson, Heléne, et al.
Publicado: (2010)